Literature DB >> 2870354

Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.

R O'Donovan, D Baldwin, M Hammer, C Moniz, V Parsons.   

Abstract

For two years all 28 patients undergoing hospital haemodialysis were switched from a dialysate magnesium (Mg) of 0.85 mmol/l to one containing none. Oral aluminium hydroxide was discontinued, and magnesium carbonate was substituted as a phosphate binder. After 24 months on this regimen predialysis aluminium concentration had fallen significantly. There was no significant change in predialysis phosphate, which remained above the normal range; nor was there evidence of increased secondary hyperparathyroidism as judged by parathyroid hormone immunoassay and biochemical or clinical criteria. Predialysis Mg concentrations tended to fall towards the normal range. Aluminium-containing phosphate binders seem to be unnecessary for the control of dialysis hyperphosphataemia. Magnesium carbonate may be an alternative and less toxic compound.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870354     DOI: 10.1016/s0140-6736(86)90987-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

Review 3.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

4.  Preventing bone disease requires diligent management in patients with renal failure.

Authors:  F O Kolb
Journal:  West J Med       Date:  1994-05

5.  Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.

Authors:  T H Ittel; C Schäfer; H Schmitt; U Gladziwa; H G Sieberth
Journal:  Klin Wochenschr       Date:  1991-01-22

6.  Inverse correlation between serum magnesium and parathyroid hormone in peritoneal dialysis patients: a contributing factor to adynamic bone disease?

Authors:  Mingxin Wei; Khaled Esbaei; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 7.  Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Authors:  Víctor Lorenzo Sellares; Armando Torres Ramírez
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 9.  Beneficial effects of magnesium in chronic renal failure: a foe no longer.

Authors:  Ioannis P Tzanakis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2008-12-30       Impact factor: 2.370

10.  Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

Authors:  Christopher W McIntyre; Pearl Pai; Graham Warwick; Martin Wilkie; Alex J Toft; Alastair J Hutchison
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.